AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
JN
Jupiter NeurosciencesClinical-stage biotech developing JOTROL, a proprietary high-bioavailability resveratrol platform targeting neuroinflammation, mitochondrial dysfunction, and longevity indications including Parkinson's and Alzheimer's disease.
1 Pulse story
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Attovia TherapeuticsJupiter Neurosciences
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsJupiter Neurosciences
Biotech
Sector
Biotech
2023
Founded
—
San Carlos, CA
HQ
Jupiter, Florida
Public (ATTO)
Status
Public (JUNS)
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Jupiter Neurosciences investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Jupiter Neurosciences.